13.07.2020 | short review | Ausgabe 3/2020
San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor 2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)
- Zeitschrift:
- memo - Magazine of European Medical Oncology > Ausgabe 3/2020
Wichtige Hinweise
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Summary
At the 2019 San Antonio Breast Cancer Symposium, new data on the management of heavily pretreated human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer were discussed. The phase 3 HER2CLIMB and the phase 2 DESTINY-Breast01 trials investigating tucatinib and trastuzumab deruxtecan, respectively, have met their primary endpoints.
In an early disease setting, four studies investigated whether image-guided biopsies could identify patients with a pathologic complete response (pCR) to neoadjuvant chemotherapy, thus allowing safe omission of surgery. As residual disease was missed in a significant number of cases, these trials could not confirm data from smaller previous studies.